miRNA-21 combined with cisplatin inhibits glycolysis and induces cell death through the PI3K/AKT/mTOR/HIF-1α pathway, improves the cytotoxicity of cisplatin, and provides a theoretical basis for the treatment of cisplatin-resistant non-small cell lung cancer. Here, AKT1 is linked to non-small cell lung carcinoma.